Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Obudanersen · ION582

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: UBE3A · developed by IONIS PHARMACEUTICALS

Phase 3 Most advanced trial
IONS Developer
1 Registered trials

What is Obudanersen?

Obudanersen (ION582) is an antisense oligonucleotide administered by intrathecal injection. It is being studied in Angelman Syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ION582
Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
UBE3A
Mechanism
Gene silencing: UBE3A
Therapy area
Neurology
Developer
IONIS PHARMACEUTICALS (IONS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
M9NPL5PYM6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07782827 Phase 3 Angelman Syndrome Recruiting IONS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Angelman Syndrome

More from IONIS PHARMACEUTICALS

Donidalorsen FDA approved Olezarsen FDA approved Zilganersen FDA approved BIIB094 Phase 1 ION224 Phase 2 ION269 Phase 1 ION337 Phase 1/2 ION356 Phase 1 ION363 Phase 3 ION440 Phase 1/2 ION464 Phase 1 ION717 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.

Follow IONS, the company behind Obudanersen

See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IONS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.